SARS-CoV-2 nucleoprotein increases infectivity of spike-based pseudoviruses

In a recent study conducted at the Indian Institute of Science Education and Research, India, a team of scientists screened specific genes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to identify factors that may contribute to viral infectivity.

Their findings suggest that SARS-CoV-2 nucleoprotein significantly increases the infectivity of spike-pseudotyped lentiviral particles, making the particles less susceptible to soluble angiotensin-converting enzyme 2 (ACE2)-mediated neutralization. The study is currently available on the bioRxiv* preprint server.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Background

SARS-CoV-2, the causative pathogen of coronavirus disease 2019 (COVID-19), is an enveloped RNA virus with a genome size of about 30 kb. Among various structural proteins encoded by the viral genome, the spike glycoprotein on the viral envelop plays an important role in viral infectivity. Upon binding to the host ACE2, the spike protein undergoes various structural rearrangements, which ultimately lead to entry of SARS-CoV-2 into the host cells.

Because of robust immunogenicity, the spike protein is frequently used in laboratories to generate pseudotyped lentiviral or retroviral particles. These particles are particularly helpful in screening and identifying spike-specific neutralizing antibodies or small molecule inhibitors that have been developed to combat COVID-19. However, such SARS-CoV-2 spike-pseudotyped lentiviral systems do not provide information about other viral genes that may potentially contribute to the overall viral infection cycle.

In the current study, the scientists aim to explore the impacts of specific SARS-CoV-2 genes on viral infectivity.

Study design

Using spike-pseudotyped lentiviral particles, the scientists conducted an unbiased screening of 24 genes of SARS-CoV-2, including open reading frames (ORFs) and structural and non-structural protein genes. Specifically, they evaluated whether any of these genes can potentially modulate viral infectivity as well as susceptibility to ACE2-IgFc microbody-mediated neutralization. The ACE2-IgFc microbody, which was generated by fusing ACE2 ectodomain with the Fc region of human IgG, has been considered as a potent spike-pseudovirus neutralizing agent.

Important observations

The scientists transduced ACE2-expressing human embryonic kidney cells with pseudoviruses produced in the presence of specific SARS-CoV-2 genes and assessed the viral infectivity. By analyzing the screening dataset, they observed that SARS-CoV-2 nucleoprotein significantly increased the infectivity of spike-pseudoviruses.

Given the nucleoprotein-mediated induction of viral infectivity, the scientists next investigated whether increased infectivity facilitates the virus evading ACE2-IgFc microbody-mediated neutralization. Using histidine-based pull-down assays, they tested the specific interaction between ACE2-IgFc microbody and spike-pseudotyped lentiviral particles. They observed that the stably expressed microbody had a high affinity toward spike-based viral particles.

To determine the infection-creating ability of viral particles under the influence of nucleoprotein, the scientists generated spike-pseudoviruses with and without nucleoprotein co-transfection and incubated these particles with different concentrations of ACE2-IgFc microbody. Next, they used this particle-microbody mixture to transduce ACE2-expressing cells and observed that spike-pseudoviruses expressing nucleoprotein were less susceptible to ACE2 microbody-mediated neutralization than those not expressing nucleoprotein. Specifically, they observed that a higher amount of microbody is required to effectively block the entry of nucleoprotein-expressing spike-pseudoviruses into host cells.  

To investigate how the nucleoprotein may influence viral infectivity, the scientists conducted a series of biochemical analyses and observed that nucleoprotein improved the spike-pseudovirus quality and infectivity by significantly increasing the incorporation of spike protein into the virions.

Study significance

The study findings reveal that SARS-CoV-2 nucleoprotein increases the infectivity of spike-pseudotyped viral particles by improving the enrichment of spike protein into the virion. Moreover, the nucleoprotein-mediated induction of particle infectivity is not associated with enhancement of sensitivity toward spike binding-based neutralizing agents.

Specifically, the study highlights the importance of modifying spike-based pseudoviruses with specific viral genes known to influence viral infectivity. Such advancement in lentiviral spike particle systems can significantly benefit the large-scale screening of anti-COVID-19 therapeutic agents.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • Apr 5 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Dr. Sanchari Sinha Dutta

Written by

Dr. Sanchari Sinha Dutta

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world. She has a Bachelor of Science (B.Sc.) degree and a Master's of Science (M.Sc.) in biology and human physiology. Following her Master's degree, Sanchari went on to study a Ph.D. in human physiology. She has authored more than 10 original research articles, all of which have been published in world renowned international journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dutta, Sanchari Sinha Dutta. (2023, April 05). SARS-CoV-2 nucleoprotein increases infectivity of spike-based pseudoviruses. News-Medical. Retrieved on November 24, 2024 from https://www.news-medical.net/news/20210217/SARS-CoV-2-nucleoprotein-increases-infectivity-of-spike-based-pseudoviruses.aspx.

  • MLA

    Dutta, Sanchari Sinha Dutta. "SARS-CoV-2 nucleoprotein increases infectivity of spike-based pseudoviruses". News-Medical. 24 November 2024. <https://www.news-medical.net/news/20210217/SARS-CoV-2-nucleoprotein-increases-infectivity-of-spike-based-pseudoviruses.aspx>.

  • Chicago

    Dutta, Sanchari Sinha Dutta. "SARS-CoV-2 nucleoprotein increases infectivity of spike-based pseudoviruses". News-Medical. https://www.news-medical.net/news/20210217/SARS-CoV-2-nucleoprotein-increases-infectivity-of-spike-based-pseudoviruses.aspx. (accessed November 24, 2024).

  • Harvard

    Dutta, Sanchari Sinha Dutta. 2023. SARS-CoV-2 nucleoprotein increases infectivity of spike-based pseudoviruses. News-Medical, viewed 24 November 2024, https://www.news-medical.net/news/20210217/SARS-CoV-2-nucleoprotein-increases-infectivity-of-spike-based-pseudoviruses.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Could vitamin D help COVID-19 patients? Meta-analysis highlights potential ICU reduction